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Abstract 
Background: Treatment of non-clear cell RCC remains controversial despite several recent 
prospective studies of targeted therapies (TT). Often VEGF and mTOR inhibitors are used, 
extrapolating the data from use of these agents in clear cell RCC. 
Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to 
determine mChRCC outcomes in the targeted therapy era. The endpoints were overall response, 
overall survival (OS) and time to treatment failure (TTF). The 2 latter were estimated using the 
Kaplan-Meier method.  
Results: 91 mChRCC patients from 26 centers were included. Median follow-up from date of 
first metastasis was 6.1 years (range: 0-13.9). Median overall survival was 37.9 months (95%CI: 
21.4 to 46.8) from diagnosis of metastatic disease. Among the 61 patients who received TT, 50 
(82%) were treated with antiangiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS 
in patients receiving a first line of AA was 8.7 months (95%CI: 5.2-10.9) and 22.9 months 
(95%CI: 17.8-49.2) versus 1.9 (95%CI: 1.0-6.0) and 3.2 months (95%CI: 2.3-Not Evaluable) 
with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and 
mTOR inhibitors TT while controlling the effect of the IMDC score and no significant difference 
between AA and mTOR inhibitors was observed for TTF (p= 0.26) or for OS (p=0.55). 
Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT 
and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.  
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Introduction 
Over the past 12 years, the therapeutic arsenal against renal cell carcinoma (RCC) has widely 
expanded, with median overall survival increasing to almost 30 months in recent studies
1
. 
Prospective studies have shown that targeted therapy (TT) increases overall survival (OS) in 
metastatic clear cell, but the benefit in the other subtypes remains unclear. 
Chromophobe renal cell carcinoma (ChRCC) is the second commonest form of non clear cell 
RCC (nccRCC) (4-6%) after papillary RCC (10-15%)
2
. Systemic therapy targeting  VEGF and 
mTOR pathways have shown some efficacy in nccRCC, but to date little is known about the 
activity of monoclonal antibody directed against the program death 1 (PD 1)/ program death 
ligand 1 (PDL 1) pathway
3
, and newer VEGF TT
4
. Indeed, two randomized studies  investigated 
targeted therapy in a pool of mixed non clear cell histologies
5,6
 and few prospective single arm 
trial (RAPTOR
7
, SUPAP
8
) focus on papillary RCC. 
First described by Thoenes in 1985
9
, ChRCC probably derived from the intercalated cells of the 
collecting duct system. Surgical cohorts suggest that localized ChRCC displays a more favorable 
prognosis than papillary or clear cell RCC (ccRCC) with only 1.5% -8.6% of patients developing 
recurrence or metastasis
10,11
 and a specific mortality around 2%
12,13
. 
Most of the data about metastatic ChRCC (mChRCC) comes from retrospective small series (3 to 
37 patients) or rare phase 2 studies enrolling a heterogeneous population of nccRCC so then no 
standard of care is defined in ESMO
14
 and NCCN guidelines
15
 for mChRCC patients. In our 
study, we identified a large cohort of mChRCC to describe clinical outcomes with the use of TT. 
 
Methods 
Study design and population 
In 2012, we initiated a retrospective chart review of mChRCC patients treated within the French 
kidney group of the GETUG (Groupe d’Etude des Tumeurs Uro génitales) and the Renal Cross 
Channel Group (RCCG). Eligibility criteria included adult patients who had measurable disease 
by RECIST (Response Evaluation Criteria in Solid Tumors) and received TT. ChRCC diagnosis 
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was performed by local pathology assessment. Standardized chart review collected date of 
diagnosis, age at diagnosis, gender, date of first metastasis, number and type of metastatic site at 
the initiation of systemic therapy and prognostic factors according to the IMDC risk model
16
. No 
central pathology review was provided, imaging was not standardized and response by RECIST 
was determined locally. 
 
Statistical Analyses 
The patients’ characteristics (sex, age at diagnosis, KPS, number of metastases, IMDC risk 
model, MSKCC classification, prior nephrectomy and grade) were described (median and 
interquartile (IQR) for continuous variables and frequency for categorical variables) in TT 
patients and overall. Median follow-up was estimated by the Schemper’s method17 from the date 
of first-line therapy for patients treated with TT. For TT patients, the different types of TT 
classified as anti-angiogenic (AA: sunitinib, sorafenib, pazopanib and bevacizumab) or mTOR 
inhibitors (temsirolimus, everolimus) and the number of lines of therapy were reported. The 
patients’ characteristics of these 2 groups were also reported and compared. The best response 
was determined by local assessment every 8-12 weeks according to RECIST 1.1 criteria as 
complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) 
and the objective response rate (ORR) defined as CR/PR, SD or PD were described. The latter 
was compared between the 2 classes of targeted therapies by a Fisher’s exact test. The time to 
failure (TTF) was defined as the time from the date of first-line therapy to discontinuation of 
treatment for any reason, including disease progression, treatment toxicity, and death. Patients 
with no treatment failure were censored at the date of last follow up. Overall Survival (OS) was 
defined as the time from the first-line therapy to death. Patients alive were censored at the date of 
last follow-up. These 2 time-to-events were estimated by the Kaplan-Meier (KM) method and 
median with its 95% confidence interval (CI) was reported. We compared TTF and OS between 
(i) IMDC prognostic groups (log-rank test) and (ii) targeted therapies (AA and mTOR) (stratified 
log-rank test). For the latter, no interpretation can be done based on the KM estimation 
considering the observational type of this study. The cut-off date for the analyses was December 
31 2015. The statistical analyses were done with SAS software 9.4. (SAS Institute). 
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Results 
Overall mChRCC cohort 
We collected data from 91 mChRCC patients from 26 centers in 4 countries (France, UK, Italy 
and Australia) (Figure 1). Patients had been diagnosed from July 1997 to April 2013. Median 
follow-up from date of first metastasis was 6.1 years (range: 0-13.9). Patient and tumor 
characteristics are described in Table 1. Median age at diagnosis was 58 years (IQR: 49.0- 66.6) 
with a majority of men (64.4%, n= 58). Most patients had a nephrectomy (92%, n=83). Median 
time from diagnosis to metastasis was 9.4 months (IQR: 0.7-37.7). Median time from metastasis 
to first-line treatment was 3.5 months (IQR: 1.1-13.4). In our cohort, 24.4% (n=22) had 
metachronous metastases while 75.6% (n=68) were synchronous. Abdominal lymph nodes were 
the most common site of metastasis while lung and liver metastases appeared to be less common. 
International Metastatic RCC Database Consortium (IMDC risk model) prognosis groups were 
favorable for 10.3% (n=6), intermediate for 69.0% (n=40) and poor for 20.7% (n=12) patients. 
The score was not available for 32 patients (35.6 %) because of missing data. The median OS 
from date of first metastasis was 37.9 months (95%CI 21.4 to 46.8) (58 deaths). 
 
mChRCC patients treated with targeted therapy 
Sixty eight of the 90 mChRCC patients received medical treatment, mostly TT (n=64), or other 
systemic therapy: interferon alone (n=2), vinflunine or hormonal therapy (one each). The 
remaining 22 patients never received systemic therapy, among which 6 were treated with surgery 
alone on oligometastatic disease, to delay systemic therapy (Figure 1). Among the 64 patients 
treated with TT, 3 were excluded from the analysis because of missing data. The median follow-
up of the 61 treated patients from date of first line of treatment was 4.1 years (range: 1.1-7.7). 
The IMDC risk model was analyzed in 72.1% (n=44) of 61 patients: 2.3% (n=1) patients were in 
the favorable prognosis group, 77.3% (n=34) in the intermediate prognosis group and 20.5% 
(n=9) in the poor prognosis group. Out of the 61 patients, 50 (82.0%) and 11 (18.0%) were 
treated in first line by AA and mTOR inhibitors, respectively. Second line therapy was 
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administered in 30 (49.2%) patients: 14 patients were treated with AA (46.7%) and 16 (53.3%) 
with mTOR and third line in 11 (18.0%) patients. The patients’ characteristics treated with AA 
and mTOR were significantly different except for gender and the number of metastatic sites. It is 
interesting to note that most of AA patients had intermediate IMDC risk group (n=32, 88.9%) 
compared to mTOR patients (n=2, 25.0%) (p<0.001, n=44) (Table 1). The different types of TT 
are reported in table 2. 
 
Response rate 
Among patients treated by targeted therapy, the response were: CR: 1.9% (n=1), PR: 23.1% 
(n=12), SD: 44.2% (n=23) and PD: 30.8% (n=16) (9 had missing data) (Table 3). The ORR was 
CR/PR: 25.0 % with no significant difference between AA (CR/PR: 28.9% (n=13), SD: 42.2% 
(n=19) and PD: 28.9% (n=13)) and mTOR inhibitors (CR/PR: 0.0% (n=0), SD: 57.1% (n=4) and 
PD: 42.9% (n=3)) (p=0.28, Fisher’s exact test). Even if the observed numerical difference of 
ORR between AA and mTOR is important (28.9% vs 0.0%) the statistical test is not significant 
due a lack of power. However, even if this difference had been significant, caution is necessary in 
interpreting this result because of the risk of confounding bias due to the observed unbalance of 
patients’ characteristics between AA and mTOR (Table 1). Furthermore, clinical benefit (defined 
as CR/PR/SD) appears similar in both groups (71.1% vs 57.1% in AA and mTOR, respectively 
p=0.66). 
 
Time to Treatment Failure 
The median TTF from the date of first-line therapy for mChRCC was 7.2 months (95%CI: 4.1-
9.5) with 61 events. Median TTF was 8.7 months (95%CI: 5.2-10.9) and 1.9 months (95%CI: 
1.0-6.0) in patients treated with AA and mTOR inhibitors, respectively (Figure 2A). We reported 
unadjusted Kaplan-Meier curves between these 2 groups only for description. Median TTF was 
significantly higher in intermediate IMDC group (8.0 months (95%CI: 4.1-13.6)) compared to 
poor IMDC group (2.3 months (95%CI: 0.7-8.0)) (p=0.001) (Figure 2B). The favorable IDMC 
group was not collapsed with intermediate group. Given the limited number of patients to 
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construct a model to estimate the treatment effect controlling for several confounders, a stratified 
log-rank test was used to compare the targeted therapies (AA and mTOR inhibitors) while 
controlling the effect of the IMDC score. No significant difference between AA and mTOR 
inhibitors was observed for TTF (p= 0.26). 
 
Overall Survival 
Median OS was 20.8 months (95%CI: 11.6-35.2) in the treated population with 43 deaths 
(70.5%). Median OS was 22.9 (95%CI: 17.8-49.2) and 3.2 months (95%CI: 2.3-Not Evaluable) 
in patients treated by AA and mTOR inhibitors respectively (Figure 2C). Median OS was 22.8 
months (95CI%: 13.7-82.4) and 4.3 months 95%CI: 1.1-35.2) in intermediate and poor prognosis 
group according to IMDC risk model respectively (p<0.005, log rank test) (Figure 2D), one 
patient has favorable prognosis. With stratified log-rank test to compare AA and mTOR 
inhibitors while controlling the effect of the IMDC score, no significant difference between AA 
and mTOR inhibitors was observed for OS (p= 0.55). 
 
Discussion 
We report a large series of patients with mChRCC treated with TT. For several decades, nccRCC 
has been considered as a global entity. Recently two dedicated randomized phase 2 trials 
compared everolimus and sunitinib in patients with metastatic nccRCC (Supplementary Table 1). 
In the first trial (ESPN), median PFS from first-line therapy was 6.1 months (95%CI: 4.2-9.4) 
with sunitinib and 4.1 months (95%CI: 2.7-10.5) with everolimus and median overall survival 
(OS) was 16.2 months (95%CI: 14.2-NA) with sunitinib and 14.8 months (95%CI: 8.0-23.4) with 
mTOR inhibitors (p= 0.18)
5
. The second trial (ASPEN), median PFS was 8.3 (80%CI: 5.8-11.4) 
versus 5.6 (80%CI: 5.5-6.0) months with sunitinib and everolimus respectively
6
; hazard ratio 
(HR) was 1.41 (80%CI: 1.03-1.92), (p= 0.16). Median OS was 31.5 months (80%CI: 14.8-NR) 
with sunitinib versus 13.2 months (80%CI: 9.7-37.9) with everolimus. Respectively, mChRCC 
patients accounted for 12/72, and 16/108 patients in ESPN and ASPEN. RECORD-3, a 
randomized phase 2 trial in metastatic RCC, comparing the sequence of everolimus followed by 
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sunitinib at progression to the opposite sequence, enrolled both ccRCC and nccRCC patients. In 
the subgroup analysis of 66 nccRCC patients, everolimus did not yield better results than 
sunitinib as first line therapy; median PFS were 5.1 and 7.2 months respectively, (HR: 1.54 
95%CI: 0.86-2.75), mChRCC accounted only for 2% and 3% of patients in each arm
18
. A very 
recent systematic review with inter-trial meta-analysis investigated patients with metastatic 
nccRCC and concludes a trend toward favoring AA for PFS and OS compared to mTOR, but 
statistical significance was not reached
19
. 
 In 2007, the Global ARCC trial suggested that responses were seen with temsirolimus in 
nccRCC
20
; among 73 patients with nccRCC, median OS was 11.6 (95%CI: 8.4-14.5) with 
temsirolimus vs 4.3 (95%CI: 3.2-7.3) with IFN alone
21
. Stadler reported in nccRCC subgroup 
analysis of sorafenib expanded access program (EAP) (n= 588), a median PFS of 24 weeks (n= 
202)
22
. Within the sunitinib EAP (n= 4349), Gore reported a median PFS of 7.8 months (95%CI: 
6.3-8.3) compared to 10.9 (95%CI: 10.3-11.2) months for those with ccRCC, and OS was 13.4 
months (95%CI: 10.7-14.9) for nccRCC vs 18.4 months (95%: 17.4-19.2) in the entire 
population
23
. 
Before the TT era, Motzer reported that median OS was 9.4 months for a nccRCC cohort, with 29 
months for mChRCC
24
 subgroup. In the TT era, the subgroup analyses from Kroeger et al, 
reported median OS of 12.8 months (95%CI: 11.0-16.1 months) for all nccRCC cohort
16
; median 
OS was 27.1 months for mChRCC (95%CI: 12.6-75.3 months), 14.0 months for pRCC (95%CI: 
10.9-17.1 months), and 10.1 months (95%CI: 5.1-13.2 months) for unRCC patients. Furthermore, 
it demonstrated the applicability of the IMDC prognostic model in nccRCC treated with first line 
TT: median OS of the three IMDC risk groups were 31.4 months (95%CI: 14.2-78.3 months), 
16.1 months (95%CI: 12.5-18.7 months), and 5.1 months (95%CI: 2.7-7.1 months) respectively.  
In our study, median OS was 22.8 months (95%CI: 13.7-82.4) in intermediate prognosis risk 
group and 4.3 months (95%CI: 1.1-35.2) in poor prognosis risk group (p<0.005, log rank test) 
(Figure 2D). Similarly, in the retrospective study cohort from Choueiri et al. median OS was 19.4 
months in a mixed cohort of pRCC and ChRCC patients treated with sunitinib
25
.  
In 2016, Keizman et al. investigated retrospectively the clinical outcome with AA for mChRCC 
within 36 patients from 10 centers
26
. Metastatic ChRCC patients were individually matched to 
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metastatic ccRCC patients by known prognosis factors. Treatment outcome was not different 
between metastatic ChRCC and ccRCC patients: median PFS was 10 versus 9 months (HR: 1.4; 
p=0.6). Median OS was 26 versus 25 months (HR: 1.15; p=0.7).  
In our study, OS was 20.8 months (95%CI: 11.6-35.2) for patients treated with TT, and median 
OS from diagnosis of metastatic disease for the 90 patients was 37.9 months (CI95%: 21.4-46.8).  
Our work is not without limitations inherent to its retrospective nature. Our work is not without 
limitations inherent to its retrospective nature. Among them, are the lack of central radiological 
review for the assessment of response and the lack of central pathological review. Given the 
limited number of patients, no multivariable analyses were performed. Moreover the major 
imbalance between AA and mTOR populations prevents us from drawing firm conclusions on the 
specific role of mTOR inhibition in this setting. Indeed, we observed that the majority of our 
mChRCC cohort (81.9%) was treated with first line AA; this led to an attrition bias because the 
small number of patients treated with first-line mTOR inhibitors largely had poor prognosis 
features resulting to a short survival of patients treated with mTOR. Among the 11 patients, 6 
belonged to the poor IMDC risk model group, 2 were intermediate risk and 3 had missing data 
about IMDC risk model score. At the time of analysis 8/11 (72.8%) of patients with mTOR 
inhibitors had died, including 7 within the first month of TT. This explain the median TTF of 1.9 
(95%CI: 1.0-6.0) and OS of 3.2 months (95%CI: 2.3-Not Evaluable). When a stratified log-rank 
test was used to compare AA and mTOR inhibitors TT in order to control the effect of the IMDC 
score, no significant difference between AA and mTOR inhibitors was observed for TTF (p= 
0.26) and OS (p=0.55). 
To our knowledge, our cohort is the largest series of mChRCC treated with TT, providing a 
benchmark for future trials in this rare disease. Unfortunately, each of the recent prospective 
trials investigating nccRCC failed to include more than 15 mChRCC
5,6,18
. We report on 61 
mChRCC treated with TT within a collaborative groups to provide valuable insight into rare renal 
tumors. However the weakness of the retrospective design limits results interpretation. Certainly, 
VEGF inhibition is a reasonable front line and mTOR inhibitors provides clinical benefits to 
some patients. 
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Conclusion 
Metastatic ChRCC is a rare entity with no specific TT recommended. We describe the largest 
cohort, to date, of mChRCC treated with TT and illustrate the ability of an academic consortium 
to provide unique information on rare histologies. Emerging data from the genomic landscape of 
ChRCC may provide new insights into novel druggable targets in these patients
27
. 
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Table 1: Patients’ and tumor characteristics for all patients (n=90) and for patients treated by 
targeted therapy (n=61) 
Characteristics All patients 
(n=90) 
 
 
N (%) 
Patients receiving systemic targeted therapy 
(n=61)* 
 
 
All 
N (%) 
Anti angiogenic (n=50) 
N (%) 
mTOR inhibitors (n=11) 
N (%) 
p-value‡ 
Country 
 France 
 UK 
 Italy 
 Australia 
 
40 (44.4) 
43 (47.8) 
6 (6.67) 
1 (1.1) 
 
35 (57.4) 
19 (31.1) 
6 (9.8) 
1 (1.6) 
 
26 (52.0) 
18 (36.0) 
5 (10.0) 
1 (2.0) 
 
9 (81.8) 
1 (9.1) 
1 (9.1) 
0 (0.0) 
0.2847 
Sex 
 Male 
 Female 
 
58 (64.4) 
32 (35.6) 
 
36 (59.0) 
25 (41.0) 
 
28 (56) 
22 (44) 
 
8 (73) 
3 (27) 
0.4999 
Age at diagnosis (years) 
 Median (IQR) 
 
58 (49 – 66) 
 
57 (49 – 63) 
 
55 (47 – 62) 
 
62 (58 – 71) 
0.0356 
KPS 
 ≥80% 
 <80% 
 Missing 
 
56 (76.7) 
17 (23.3) 
17 
 
40 (75.5) 
13 (24.5) 
8 
 
36 (83.7) 
7 (16.3) 
7 
 
4 (40.0) 
6 (60.0) 
1 
0.0090 
Number of metastases 
 0-1 
 >1 
 Missing  
 
45(50.6) 
44(49.4) 
1 
 
27 (44.0) 
34 (55.7) 
0 
 
23 (46.0) 
27 (54.0) 
 
4 (36.4) 
7 (63.6) 
0.7403 
IMDC Risk model‡ 
 favorable 
 intermediate 
 poor 
 Missing 
 
6 (10.3) 
40 (69.0) 
12 (20.7) 
32 
 
1 (2.3) 
34 (77.2) 
9 (20.5) 
17 
 
1 (2.8) 
32 (88.9) 
3 (8.3) 
14 
 
0 (0.0) 
2 (25.0) 
6 (75.0) 
3 
0.0003 
MSKCC£ 
 0 
 1 
 2 
 3 
 Missing 
 
10 (17.5) 
23 (40.4) 
14 (24.6) 
10 (17.5) 
33 
 
4 (9.3) 
20 (46.5) 
12 (27.9) 
7 (16.3) 
18 
 
4 (11.1) 
19 (52.8) 
10 (27.8) 
3 (8.3) 
14 
 
0 (0.0) 
1 (14.3) 
2 (28.6) 
4 (57.1) 
4 
0.0192 
Prior nephrectomy  
 No  
 Yes 
 
7(7.8) 
83 (92.2) 
 
4 (6.6) 
57 (93.4) 
 
0 (0.0) 
50 (100.0) 
 
4 (36.4) 
7 (63.6) 
0.0006 
Grade  
 1  
 2 
 3 
 4 
 
3(4.4) 
11 (16.2) 
32 (47.1) 
22 (32.4) 
 
1 (2.0) 
9 (18.0) 
23 (46.0) 
17 (34.0) 
 
1 (2.3) 
8 (18.2) 
23 (52.3) 
12 (27.3) 
 
0 (0.0) 
1 (16.7) 
0 (0.0) 
5 (83.3) 
0.0241 
15 
 
 Missing  22 11 6 5 
*Beyond the 64 patients treated by systemic therapy 3 patients were excluded for missing data 
IQR: Interquartile range, ‡ IMDC = International Metastatic Renal Cell Carcinoma Database 
Consortium, £ MSKCC = Memorial Sloan Kettering Cancer Center. 
‡: p-value was computed using the Fisher’s exact for categorical data or the Kruskal-Wallis test 
for continuous data
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Table 2: Type of targeted therapy for 61 treated patients 
 
Targeted therapy N (%) 
Anti angiogenic 50 (82.0) 
 Sunitinib 40 (65.7) 
 Pazopanib 2 (3.2) 
 Sorafenib 5 (8.2) 
 IFN_bevacizumab 1 (1.64) 
 Bevacizumab based combination 2 (3.28) 
mTOR inhibitors 11 (18.0) 
 Temsirolimus 4 (6.7) 
 Everolimus 7 (11.5) 
 
17 
 
Table 3: Best Response Rates, Time to treatment failure and Overall Survival in patients treated 
by targeted therapy (n=61) 
 
 Treated patients (n=61)* 
 AA mTOR All 
Best Response 
CR/PR/SD/PD (n)** 
CR/PR/SD/PD (%) 
 
1/12/19/13 
2.22/26.7/42.2/28.9 
 
0/0/4/3 
0/0/57.1/42.9 
 
1/12/23/16 
1.9/23.1/44.2/30.8 
 
ORR** 
CR+PR/SD/PD (n) 
CR+PR/SD/PD (%) 
 
 
13/19/13 
28.9/42.2/28.9 
 
 
0/4/3 
0/57.1/42.9 
 
 
13/23/16 
25.0/44.2/30.8 
 
No of deaths 
 
35 
 
8 
 
43 
Median TTF (95%CI) 8.7 (5.2-10.9) 1.9 (1.0-6.0) 7.2 (4.1-9.5) 
Median OS (95%CI) 22.9 (17.8-49.2) 3.2 (2.3-NE) 20.8 (11.6-35.2) 
 
* Three patients were excluded for missing data, AA: antiangiogenic, mTOR: mTOR inhibitors. 
** Nine patients were excluded from BR and ORR analysis for missing data, BR = best response, 
CR =complete response, PR= partial response, SD = stable disease, PD = progression disease, 
ORR = objective response rate, CI = confidence interval; NE = not evaluable; TTF = time to 
treatment failure, OS = overall survival
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Table 4: Metastatic site for entire cohort * 
 
Metastatic site N=89 (%) 
Abdominal nodes 37 (41.6) 
Lung metastasis 30 (33.7) 
Bone metastasis 20 (22.4) 
Mediastinal nodes 17 (19.1) 
Liver metastasis 17 (19.1) 
Brain metastasis 5 (5.6) 
Others (peritoneal relapse for majority) 28 (31.5) 
 
*: 1 patient has missing data for details of metastatic sites 
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Supplementary Table 1: Clinical outcomes described of mChRCC in literature 
 
References 
 
Trial design 
 
N 
mChrcc(%) 
Median OS 
(95% CI) (months) 
Median PFS 
(95% CI) (months) 
nccRCC ChRCC nccRCC ChRCC 
AA mTOR AA m TOR AA mTOR AA mTOR  
Motzer RJ et al. 
RECORD-3 Phase II randomized trial 
comparing sequential first-line everolimus and second-line sunitinib versus first-
line sunitinib and second-line everolimus in patients with metastatic renal cell 
carcinoma. 
J Clin Oncol 2014 
open-label, 
randomised 
phase 2 
11/207 
 
- - - - 7.2 (5.4-
13.8) 
5.1 (2.6-
7.9) 
- - 
Armstrong AJ et al 
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell 
carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
Lancet Oncol. 2016 
open-label, 
randomised 
phase 2 
16/108 31.5 
(14.8-
NR) 
13.2 
(9.7-
37.9) 
NS NS 8.3 
(80%5.8-
11∙4) 
5.6 
(80%5.5-
6.0)  
5.5 (80% 
3.2–19.7) 
11.4 
(80%5.7–
19.4) 
Tannir et al 
ESPN Everolimus Versus Sunitinib Prospective Evaluation in 
Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): 
A Randomized Multicenter Phase 2 Trial 
randomized 
phase 2 
12/72 16.2 14.8 31.6 (14.2–
NA) 
25.1 (4.7–
NA) 
6.1 (4.2-
9.4) 
4.1 (2.7-
10.5); 
8.9 (2.9-
20.1) 
NA 
Kroeger N et al. 
.Metastatic non-clear cell renal cell carcinoma treated with targeted therapy 
agents: characterization 
of survival outcome and application of the International mRCC Database 
Consortium criteria. 
Cancer 2013 
Retrospective 
study 
37 - - 27.1 (12.6-
75.3) 
- TTF= 4.2 
(3.7-5.2) 
- - - 
Gore ME et al. 
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an 
expanded-access trial. 
Lancet Oncol 2009 
Expanded 
Access 
Program 
NA 
 
13.4 
(10.7-
14.9) 
- - - 7.8 (6.3-
8.3) 
- - - 
Tannir NMet al. 
A phase 2 trial of sunitinib in 
patients with advanced non-clear cell renal cell carcinoma. 
Eur Urol 2012 
Single arm 
phase 2 
 16.8 
(10.7-
26.3) 
 
- - - 2.7 (1.4-
5.4) 
- - - 
Lee J-Let al. 
Multicenter phase II study of sunitinib 
in patients with non-clear cell renal cell carcinoma. 
Ann Oncol 2012 
Single arm 
phase 2 
3 NR but 
25.6 (8.4 
-42.9) 
expected 
- - - 6.4( 4.2-
8.6) 
- - - 
Molina AM et al. 
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell 
carcinoma. 
Invest New Drugs 2012. 
Single arm 
phase 2 
2 - - - - 5.5 (2.5-
7.1) 
- - - 
Koh Y et al. 
Phase II trial of everolimus for the 
treatment of nonclear-cell renal cell carcinoma. 
Ann Oncol 2013 
Single arm 
phase 2 
8 - 14.0 - 21.6 - 5.2 
 
- 13.1 
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Keizman D et al 
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated 
With Sunitinib 
The Oncologist. 2016 
Retrospective 
study 
36 - - 26 (HR: 
1.15p=0.7) 
- - - 10 (HR: 
1.4; 
p=0.6).  
- 
Choueiri TK et al. 
Efficacy of sunitinib and 
sorafenib in metastatic papillary and chromophobe renal cell carcinoma. 
J Clin Oncol. 2008 
Retrospective 
study 
12 19.6 - NA - 8.6  - 10.6 - 
Voss MH et al. 
Treatment outcome with mTOR 
inhibitors for metastatic renal cell carcinoma with nonclear and 
sarcomatoid histologies. 
Ann Oncol 2014 
Retrospective 
study 
NA - 8.7 - - - 2.9 - - 
Dutcher JP et al. 
Effect of temsirolimus versus interferon-alpha on outcome of patients with 
advanced renal cell carcinoma of different tumor histologies. 
Med Oncol 2009 
Exploratory 
subgroup 
analyses from 
phase 3 
ARCC 
12 - 11.6 (8.9- 
14.5) 
- - - 7 (3.9- 8.9) - - 
NA: not assessable; TTF: Time To Treatment Failure; HR: Hazard ratio; NR: not reached; NS: 
not shown; - : not investigate in the studyFigure 1: Flow-chart 
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AA: antiangiogenic, mTOR: mTOR inhibitors. 
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Figure 2: Unadjusted Kaplan-Meier estimates of the failure-free survival in the first line targeted 
therapy between antiangiogenic (AA) and mTOR inhibitor (panel A), of the failure-free survival 
in the first line targeted therapy between intermediate IMDC risk model (coded as 1-2) and poor 
IMDC risk model (coded as 3) (panel B), of the overall survival between antiangiogenic (AA) 
and mTOR inhibitor (panel C) and of the overall survival between intermediate IMDC risk model 
(coded as 1-2) and poor IMDC risk model (coded as 3) (panel D) in targeted treated patient 
(n=61)* 
 
A 
 
B 
 
C 
 
D 
 
 
* For IMDC risk model we did not report the TTF and OS for group with favorable prognosis 
because it represents only one patient.AA: antiangiogenic, mTOR: mTOR inhibitors. 
 
 
